Cardiovascular complications are responsible not only for the high mortality, but also the morbidity of end-stage renal disease patients. Cyclic changes of fluid load, together with the altered metabolism, are responsible and are mirrored in many particular parts of the heart. A review of the mechanisms involved is presented and the role of dialysis access is highlighted.
REVIEW
misinterpreted as pure overhydration and vice versa. Various attempts to emphasize the role of heart disease in chronic kidney disease (CKD) patients have been published -from the well-known cardiorenal syndrome classification by Ronco et al (2) to the recent conclusions of the Acute Dialysis Quality Initiative XI Workgroup (3), which proposed a new classification of heart failure in ESRD patients. The latter workgroup specifically excludes patients with simple water overload and a normal heart, and focuses on those having specific echocardiographical changes. These include 3 elements: (i) ECHO evidence of structural or functional heart abnormalities; (ii) shortness of breath occurring in the absence of pulmonary disease; and (iii) the response of congestive symptoms to ultrafiltration (3) . The same group (4) selected the following 8 echocardiographic criteria of structural heart disease; it is present if at least 1 criterion is detected (see Tab. I). Although this attempt to standardize the definition of structural heart disease in ESRD patients is respectable, some important issues were missed, such as pulmonary hypertension, lack of any cardiac calcification score, and the presence of significant coronary artery disease. Moreover, their cut-off values for various pathological findings differ from the European and American guidelines for echocardiography (Tab. I).
The particular pathological changes are noted below.
Arterial disease

Characteristics
Patients suffering from ESRD are also affected by accelerated atherosclerosis (disease of the intimal arterial wall layer) and from medial calcinosis.
Etiopathogenesis
Atherogenesis is accelerated due to the higher occurrence of traditional risk factors: diabetes mellitus, arterial hypertension, changes of serum lipids, plus the uremic millieu interieur
Introduction
Patients with end stage renal disease (ESRD) usually do not die from the renal disease per se, but from cardiovascular complications. Many mechanisms are involved, and include arterial disease -accelerated atherosclerosis, medial calcinosis (Mockeberg sclerosis), and cardiac changes -especially left ventricular hypertrophy with subsequent diastolic and systolic dysfunction, and accelerated valvular degeneration leading to either stenotic or regurgitant valvular heart disease. Heart failure is a common consequence of these processes. Heart failure not only shortens the life of ESRD patients, but also it worsens their quality of life, especially due to shortness of breath, edema, and tiredness. Symptomatic hypotension (not only during hemodialysis) is also a frequent consequence. A newer entity called cardiocerebral syndrome has been described recently, emphasizing the link between heart failure and cognitive dysfunction. This association is probably even more significant in ESRD patients, who have very low values of cerebral oxygenation even without overt heart failure, and these values further decrease during hemodialysis (1).
We review various specific pathological changes associated with ESRD with particular interest in dialysis arteriovenous access.
Heart complications are influenced by the cyclic water load changes. Thus, the symptoms of heart failure can be plays a role. Disturbances in calcium-phosphate metabolismespecially the secondary hyperparathyreoidism -and increased levels of fibroblast-growth factor-23 (FGF-23) are responsible.
Consequences
Both atherosclerosis and medial calcinosis increase the arterial stiffness (documented by increased pulse wave velocity) and, thus, the left ventricular afterload (reflected pressure wave reaches the aortic valve still open). Increased arterial stiffness increases myocardial oxygen demand, but decreases myocardial oxygen supply (5) . Diabetic ESRD patients have diminished coronary flow reserve even in the absence of epicardial arterial stenoses (6) . These microvascular changes are also responsible for the dialysis-induced regional left ventricular stunning (7).
Dialysis access
Arterial disease of the feeding artery worsens arteriovenous fistula (AVF) maturation and brings a higher risk of hand ischemia (8) . Korsheed et al (9) reported a decrease in pulse wave velocity, blood pressure, and total peripheral resistance pressure after successful AVF creation. Patients may develop steal in case of ipsilateral AVF and left internal mammary coronary artery bypass grafting with worsening of angina pectoris (10) . Interestingly, the presence of coronary artery disease is associated with shorter arteriovenous graft lifespan (11) .
Left ventricular hypertrophy
Characteristics
Left ventricular hypertrophy (LVH) is characterized by the increased left ventricular mass, which can be calculated by echocardiography or by magnetic resonance (see Tab. I for cut-off values). LVH already develops during the milder stages of CKD -it is present in up to 20% of patients with CKD stages 1-3 (12) and it affects 80% of ESRD patients (13) . Three phenotypes of altered left ventricular geometry are distinguished (Fig. 1) .
Etiopathogenesis
Cyclic water overload and anemia lead to eccentric LVH, while arterial hypertension results in concentric hypertrophy. (14) . At the cellular level, LVH is characterized by myocyte hypertrophy, interstitial fibrosis, apoptosis, and capillary rarefaction.
Consequences
The fall of blood pressure during hemodialysis leads not only to the activation of the sympathetic activity, but also to repeated ischemia, especially in areas with capillary rarefaction. Moreover, recent studies have documented increased local (myocardial) production of steroids, of fibroblast growth factor-23, and of angiotensin -further molecules supporting disperse myocardial fibrosis (15, 16) . The development of LVH has a direct detrimental effect on the left ventricular diastolic function.
The presence of LVH, and especially of the eccentric phenotype, is associated with a higher risk of cardiovascular and all-cause death (17), of cardiovascular events, and of a faster decline of the glomerular filtration rate in ESRD patients (18) . Eccentric hypertrophy brings a higher risk than concentric hypertrophy (19) .
Dialysis access
The association between AVF flow volume and LVH has been suspected for a long time. Movilli et al (20) 
Left ventricular dilatation
Characteristics
Left ventricular dilatation (LVD) is described either by its end-diastolic/end-systolic diameter, or its volume.
Etiopathogenesis
Volume overload represents the most powerful mechanism of LVD. Thus, the left ventricular size depends on the time interval since the previous hemodialysis and on the dry weight setting. For example, the mean diastolic volume fell from 122 to 108 mL during a single hemodialysis in our study (22) . Other causes include myocardial disease (myocarditis, cardiomyopathy), coronary artery disease, uncontrolled arterial hypertension, and advanced valvular disease of the left heart.
Dialysis access
Slight LVD was observed after AVF creation (23) . A more pronounced effect could be seen in patients with hyperkinetic heart failure due to high-flow AVF.
Regional wall motion abnormalities
Characteristics
Normal contractility in a particular segment of the left ventricle is called normokinesis; decreased contractility is hypokinesis; lacking contractility is akinesis; and the opposite (passive) contractility is dyskinesis.
Etiopathogenesis
Regional wall motion abnormalities (RWMAs) develop most frequently due to coronary artery disease (myocardial infarction-induced scar, ischemic stunning, or hibernation). A specific situation was described in ESRD patients treated by hemodialysis: the development of RWMAs during hemodialysis, especially in patients with intradialytic hypotension. These RWMAs occur also in patients without significant coronary artery disease, and microvascular changes are suspected. They last for several hours. Interestingly, dialysis-induced RWMAs can be, at least partially, prevented by an individual setting of the dialysate temperature (around 36.0°C instead of 37.0°C) (24) .
Consequences
A faster decline of systolic function was observed in patients with repeated dialysis-induced RWMAs (25) .
Dialysis access
Higher arteriovenous access flow volume was associated with lower frequency of RWMAs (26) . Theoretically, RWMAs may develop in patients with left internal mammary artery coronary bypass ipsilateral to AVF. In the latter case, we could expect ischemic RWMAs in the particular segments (usually anterior wall, septum, and apex of the left ventricle).
Left ventricular systolic (dys)function
Characteristics
The most commonly used parameter for systolic function estimation is ejection fraction (EF; stroke volume divided by end-diastolic volume) with the normal values >52%. However, clinically more important is the stroke volume per se and the cardiac output (= stroke volume × heart rate). The importance of stroke volume can be documented by the following examples: (i) diastolic volume 100 mL, EF 60%: stroke volume = 60 mL; and (ii) diastolic volume 190 mL, EF 32%: stroke volume = 60 mL.
Etiopathogenesis
Physiologically, the systolic function is directly related to contractility and preload (Frank-Starling law) and indirectly to afterload. Many mechanisms are involved in the development of left ventricular systolic dysfunction. Preload is characterized not only by the actual hydration status, but also by the heart rate (faster heart rate results in shorter diastolic filling phase) and actual filling depends on diastolic function (see below). Myocardial contractility is decreased as a result of coronary artery disease, diminished myocardial flow reserve with wall motion abnormalities, and by uremic toxins, such as the protein-bound indoxyl sulphate (27) , which stimulates myocardial fibrosis. Afterload is increased by (untreated) arterial hypertension, arterial stiffening, volume overload, and aortic valve stenosis. Clinically, significant coronary artery disease always should be excluded in the case of left ventricular systolic dysfunction. If it is present, revascularization should be indicated.
Consequences
Chronic left ventricular systolic dysfunction is a marker of increased mortality, which is even higher if both ventricles are affected (12) . Importantly, systolic dysfunction could be temporary; such as in states with volume overload, uncontrolled hypertension, or coronary artery disease. Therefore, a second echocardiography is advisable after clinical improvement/stabilization.
Dialysis access
Creation of AVF or percutaneous balloon angioplasty of an AVF stenosis could lead to de-compensation of heart failure due to the sudden requirement of cardiac output increase. It occurs in patients whose hearts are not able to adequately increase cardiac output, which is called "systemic steal" and develops with hypoperfusion of the tissues. Therefore, a dialysis catheter is usually recommended for these patients, especially with the ejection fraction below 30% and New York Heart Association classification III-IV (28) . In patients with less advanced heart failure, distal AVF (originating from the radial artery) is recommended for their lower flow volumes. Generally, smaller anastomosis should be created.
Left ventricular diastolic dysfunction
Characteristics
The term "diastolic dysfunction" includes the issues of both left ventricular relaxation and compliance, and increased filling pressures. (29) and patients with type 2 diabetes are more prone to it, according to one study (30) .
Etiopathogenesis
Frequent LVH brings conditions for the development of diastolic dysfunction in ESRD patients. The filling pressures are also significantly influenced by hydration; therefore, they change with the delay since the previous hemodialysis. Even compliance could be different at the low hydration state (after hemodialysis) and the high hydration state.
Consequences
Long-term increase of the filling pressures brings a higher risk of cardiovascular complications and mortality (22) .
Dialysis access
Increase of the left ventricular filling pressure was observed after AVF creation (23) .
Left atrial dilatation and systolic dysfunction
Characteristics
The left atrium is the most frequently dilated cardiac chamber. In the past, the cross-sectional left atrial diameter was measured during echocardiography; currently, the preferred method is the calculation of volume indexed to the body surface area. The upper-normal value is 34 mL/m 2 .
Etiopathogenesis
The wall of the left atrium is very thin; therefore, this cavity is more prone to volume changes, typical for ESRD. Another frequent stimulus to left atrial dilatation is the diastolic dysfunction of the left ventricle.
Consequences
Left atrial dilatation, and its systolic dysfunction, becomes more frequent with ageing and with longer hemodialysis history (22) . Some studies have shown higher cardiovascular morbidity of ESRD patients with a dilated left atrium (31) . The latter also increases the risk of atrial fibrillation.
Dialysis access
The creation of AVF leads to left atrial dilatation (23) .
Right ventricular dilatation and systolic dysfunction
Characteristics
The right ventricle has a complex shape, which limits the exact calculation of the ejection fraction by echocardiography. Fractional area shortening is used instead, together with tricuspid annular movement analysis.
Etiopathogenesis
The right ventricle dilates in response to pressure and volume overload (the former is worse tolerated). The most frequent etiology of right ventricular dilatation is pulmonary hypertension (see below) and hyperkinetic circulation, which is typical for ESRD patients on hemodialysis due to volume overload, anemia, inflammation, and AVF. Systolic dysfunction is a consequence, but it can also develop in acute pressure overload. The development of right ventricular dilatation and dysfunction worsens the left ventricular function not only by the reduced left ventricular preload, but also by interdependence. The latter mechanism could be explained by the fact that the whole heart is inside the pericardial sac; therefore, the increase of one chamber presses on the other and its filling becomes limited.
Consequences
Right ventricular dysfunction together with the left ventricular dysfunction are also strong negative prognostic markers in ESRD patients (4) . Interestingly, in patients with pulmonary hypertension, it is the right ventricle dysfunction that has the strongest negative impact on survival, probably due to capillary rarefaction (32) .
Dialysis access
The development of right ventricular dilatation and dysfunction was observed after percutaneous dialysis access thrombolysis (33) . AVF flow also has a role in the development of pulmonary hypertension (see below).
Pulmonary hypertension
Characteristics
Pulmonary hypertension is defined as a state with the mean pulmonary arterial pressure >25 mmHg at rest. Pulmonary artery pressure could be measured either invasively (Swan-Ganz catheter) or it could be estimated by echocardiography. Symptoms of pulmonary hypertension include shortness of breath, dizziness, fainting, leg swelling, etc. The prevalence is very high in ESRD patients and reaches up to 56% (34) .
Etiopathogenesis
Many factors contribute to pulmonary hypertension development. They include a postcapillary component (arterial hypertension, left ventricular disease, aortic and mitral valvular disease), a precapillary component (volume overload, pulmonary embolism -also from the thrombosed vascular access) and a hyperkinetic component (AVF, anemia, and inflammation, but also volume overload per se) (35) .
Consequences
The presence of pulmonary hypertension is associated with an increased hazard for all-cause mortality greater than two-fold, independent of other risk factors (36) .
Dialysis access
Pulmonary hypertension is more frequent in dialysis patients with higher AVF flow (37) , and it is at least partially reversible after flow-reducing access surgery. Nevertheless, no direct evidence of improved outcome of patients with pulmonary hypertension after flow reduction exists. Thrombus embolization could occur during the treatment of a clotted AVF, but a dialysis catheter also could be the origin, especially during its withdrawal (38) .
Cardiovascular calcification
Characteristics
Extraosseal calcification is frequent in hemodialysis patients, and this process also affects arteries (medial calcinosis and atherosclerosis) and the heart, where it could contribute to heart failure by affecting the valves.
Etiopathogenesis and consequences
Vascular calcification already appears in CKD stage 3. Procalcification factors include high levels of phosphates, parathormone, and FGF-23. On the contrary, there are protecting factors, such as fetuin and vitamin K-dependent GLA protein.
The calcification is an irreversible active process similar to bone formation; a phenotype transformation of myocytes to osteoblast-like cells develops. Calcification of the medial wall layer (mediocalcinosis) leads to increased arterial wall rigidity and lumen narrowing. As a result, organ ischemia develops. In the heart, calcification affects first valvular annuli, and later the leaflets. As a result, stenotic valvular disease (especially of aortic and mitral valves) could develop. However, valvular regurgitation could also occur -due to the restriction of leaflet mobility -which is typical for the posterior mitral valve leaflet. Interestingly, there are some common mechanisms of myocardial calcification and of left ventricular hypertrophy; FGF-23 is involved in both states.
Dialysis access
Medial calcinosis brings a higher risk of AVF-related hand ischemia, but its presence should not generally prevent the creation of native arteriovenous fistula (39) . Interestingly, vitamin D replacement medication is associated with a lower risk of AVF failure (40) .
Pericardial disease
Characteristics
Years ago, pericardial effusion was a typical finding of uremia thanks to late diagnosis of ESRD and less adequate hemodialysis. Nowadays, pericardial effusion is less frequent in well-treated ESRD patients and it affects especially patients with systemic disease. Other diseases include pericardial fat, thickening, and calcification.
Etiopathogenesis
Many factors play a role in the development of pericardial effusion: metabolic (including toxins), inadequate dialysis, connective tissue disorders, coronary artery disease, and neoplasms (41) . An increased amount of pericardial fat is linked not only to more advanced coronary calcification, but also to visceral fat and lower vitamin D levels (42) . A higher amount of pericardial fat is associated with lower cardiac output in healthy individuals (43) . Pericardial thickening and even constrictive pericarditis was also reported, but the latter is rather rare.
Consequences
The hemodynamic result of pericardial disease is impaired filling.
Dialysis access
Data regarding the relation of dialysis access and pericardial disease are sparse. One published case report (44) of cardiorenal syndrome, which includes pericardial effusion due to a large AVF, underlines the hemodynamic effects of AVF.
Other mechanisms of heart failure
Valvular disease
Valvular disease is a common problem in ESRD patients. Valve (and bioprosthesis) degeneration and calcification is accelerated. Regurgitations result mostly from the enlargement of the particular cavity; therefore, mitral regurgitation is the most common due to the enlargement of the left ventricle. Surgical and percutaneous techniques are now available for the therapy.
Atrial fibrillation
Atrial fibrillation is also common. This arrhythmia worsens ventricular filling and thus contributes to the development of heart failure. If untreated, fast ventricular response is associated with the worsening of the left ventricular systolic function due to so-called tachycardia-induced cardiomyopathy. Atrial fibrillation also increases the risk of ischemic cerebral stroke and other embolic complications. Anticoagulation therapy is a challenge in ESRD patients: warfarin accelerated extraosseal calcification, and ESRD patients were excluded from the larger controlled clinical trials of new oral anticoagulants, so data are sparse. As an alternative, left atrial appendage closure using a device or surgery are options (45) .
Types of heart failure
Two types of heart failure occur in ESRD patients: (i) classic, congestive heart failure; and (ii) hyperkinetic heart failure.
Congestive heart failure
This is determined by inadequately low cardiac output -unable to assure adequate arterial blood perfusion to all tissues at rest or during exercise. All mechanisms mentioned above could contribute to its development or it decompensation. Pathophysiology and clinical symptoms are similar to the general population. Nevertheless, the situation is complicated by AVF flow volume (AVF represents a systemic steal). In other words, part of the cardiac output is stolen by the arteriovenous access. To underline the effect of the systemic steal, the term "effective cardiac output" is sometimes used. It can be calculated by subtracting AVF flow volume from the measured cardiac output. Moreover, anemia has very similar effects. The toleration of AVF flow volume is very individual; even "usual" values, such as 700-1500 mL/min could be too high for some patients, as shown in Figure 2 . Importantly, access flow volume rises not only after vascular surgery, but also after successful percutaneous angioplasty of a severe stenosis (28) .
Hyperkinetic (high-output) heart failure
Hyperkinetic heart failure is a somewhat counterintuitive state characterized by symptoms of heart failure and (very) high cardiac output due to systemic vasodilatation, such as in obesity or liver cirrhosis; or, it can be due to large arteriovenous fistula, such as in ESRD patients. As a result, both ventricles dilate and systolic dysfunction develops, which is sometimes accompanied by secondary mitral and tricuspid regurgitation. Recently, a study from the Mayo Clinic (46) reviewed data of all patients (general population) coming for invasive hemodynamic evaluation over the last 14 years (n = 16,462). Interestingly, high cardiac output (defined as cardiac index >3.5 L/min) was present in 525 patients; only 120 of them suffered from heart failure with the lack of anemia or thyreotoxicosis. In this subgroup, arteriovenous fistula was the cause in 22%. The authors concluded that "Hyperkinetic heart failure is characterized by the activation of natriuretic peptides, expansion of plasma volume, increased ventricular filling pressure and by pulmonary hypertension." Another recent study (47) focused directly on the heart effects of the flow-reducing surgery of AVF in a group of 30 patients without clinical signs of heart failure and with an AVF flow above 1500 mL/min. The authors divided the patients according to their cardiac index (CI) into two groups: with normal CI and with high CI (>3.9 L/ min/m 2 ). Although the reduction of AVF flow was similar in both groups, only in patients with high CI were there significant heart changes: decrease of left ventricular diameter and mass, and a decrease of left atrial volume and of estimated pulmonary artery systolic pressure. Thus, this study brought the first cut-off value for the indication of accessflow-reducing surgery in asymptomatic patients with hyperkinetic AVF (CI >3.9 L/min/m 2 ). The problem is that the cardiac output could be high also thanks to other factors as well: anemia, hyperhydration, inflammation, autonomic dysfunction, etc. Indeed, higher levels of AVF flow were not associated with higher mortality in a large retrospective study (48) .
Contribution of vascular access
Both the creation of AVF or the treatment of a severe AVF stenosis lead to a sudden profound increase in flow volume, which should be generated by the heart. Physiological consequences include a decrease of afterload and an increase of preload. Further development depends not only on the heart capacity, but also on the ability of systemic arteries to dilate. In other words, systemic (tissue) arteries compete with AVF for the cardiac output, which, in turn, further increases. Indeed, in the paper by Chemla et al (49) , cardiac output decreased more than could be attributed to the change of AVF flow volume after flow-reducing surgery.
The mechanisms of the detrimental effects of AVF flow volume are discussed above. Nevertheless, although these negative links are frequently discussed, the vast majority of patients tolerate AVF very well. Even though it is known that AVF flow worsens some mechanisms (e.g., pulmonary hypertension), no study has directly documented an associated increase in mortality. Moreover, it is evident from various studies that a native arteriovenous fistula is associated with the lowest rate of complications and with the longest life expectation (50) . An arteriovenous graft has worse results and a permanent dialysis catheter is the worst. Although the role of the lowest rate of infections in arteriovenous fistulas is usually highlighted, there are probably also positive hemodynamic consequences.
The creation of AVF lowers the systemic blood pressure due to the fall of systemic vascular resistance. The percutaneous creation of central arteriovenous fistula (distal internal iliac artery to vein, flow volume 800-1000 mL/min) was recently successfully used for the treatment of resistant arterial hypertension in non-ESRD patients (51) . The glomerular filtration trajectory decreased more slowly in patients with functioning AVF in a recent retrospective study (52) . Better arterial hypertension control is one of the possible explanations. Indeed, the creation of AVF lowers arterial stiffness (53) . The same group published a study showing that higher AVF flow was associated with a lower level of observed hemodialysis-induced cardiac injury (dialysis-induced stunning) (26) .
Practical recommendations
Cardiac complications are frequent in ESRD patients. Therefore, it is advisable to examine the heart prior to access selection clinically (shortness of breath, chest pain, lung congestion) and echocardiographically. The use of native AVF is associated with lower morbidity and mortality. A permanent dialysis catheter should be reserved for patients with severe irreversible heart failure, or for those with very short life expectancy. When the development of heart failure is suspected, current hydration and flow volume should be examined. However, it should be kept in mind that AVF flow is only one of various potential mechanisms and is usually weaker than decompensated hypertension, an inadequate setting of dry weight, coronary artery disease, etc.
The most important feature of the ESRD patients' hemodynamics is the variability of findings. This is true not only for the echocardiographical results and for the clinical status, but also for the AVF flow volume. The major source of variability is the current hydration status: patients are usually overhydrated prior to hemodialysis therapy initiation. A similar situation occurs in noncompliant patients from dialysis to dialysis. Another important topic is the planning of dialysis access in patients coming with developed ESRD from the street: their overhydration negatively influences all echocardiographical findings, and extreme cases could be improperly condemned to permanent dialysis catheter. Another echocardiography or magnetic resonance image is indicated after the stabilization of dry weight (Fig. 3) .
Close cooperation of the nephrologist with a cardiologist experienced in the caveats of CKD patients is the best option for our patients. The surgery resulted in an asymptomatic increase of BNP. After 15 months, the patient experienced symptoms of heart failure: Qa rose to 1,800 mL/min, which was mirrored by a further increase of BNP, with LVD and decrease of its systolic function. AVF banding (arrow) reversed the signs and symptoms. AVF thrombosis developed after another 9 months. Thus, safe Qa was below 1,500 mL/min in this patient. AVF = arteriovenous fistula; BNP = B-type natriuretic peptide; EF = ejection fraction (left ventricle); LVDd = left ventricular end-diastolic diameter (the values in mm × 10 to make them more visible); Qa = AVF flow volume.
